The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.

Recent FDA approvals for immunotherapy drugs for treating lung cancer are exciting, but there still are many things we need to learn about this new field of cancer treatment. Cancer.Net Associate Editor Jyoti Patel, MD, answers some of the questions that surround lung cancer and immunotherapy, during Lung Cancer Awareness Month.

Immunotherapy made exciting strides in 2015. Because of its potential, ASCO named it the 2016 Clinical Cancer Advance of the Year.